Page last updated: 2024-12-07

2-fluoro-araatp

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID22842095
CHEMBL ID4570249
SCHEMBL ID8923315
MeSH IDM0107398

Synonyms (21)

Synonym
9-beta-d-arabinofuranosyl-2-fluoroadenine 5'-triphosphate
2-fluoro-araatp
2-f-araatp
9beta-d-arabinofuranosyl-2-fluoroadenine 5'-triphosphate
f-ara-atp
9h-purin-6-amine, 2-fluoro-9-(5-o-(hydroxy((hydroxy(phosphonooxy)phosphinyl)oxy)phosphinyl)-beta-d-arabinofuranosyl)-
z2ano885bi ,
unii-z2ano885bi
SCHEMBL8923315
HY-136650
CS-0132814
9-.beta.-d-arabinofuranosyl-2-fluoroadenine 5'-triphosphate
9h-purin-6-amine, 2-fluoro-9-(5-o-(hydroxy((hydroxy(phosphonooxy)phosphinyl)oxy)phosphinyl)-.beta.-d-arabinofuranosyl)-
9-.beta.-d-arabinofuranosyl-2-fluoroadenine triphosphate
fludarabine triphosphate
fludarabine-triphosphate
2-fluoro-9-{5-o-[(r)-hydroxy{[(r)-hydroxy(phosphonooxy)phosphoryl]oxy}phosphoryl]-beta-d-arabinofuranosyl}-9h-purin-6-a
hfd ,
2-fluoro-9-{5-o-[(r)-hydroxy{[(r)-hydroxy(phosphonooxy)phosphoryl]oxy}phosphoryl]-beta-d-arabinofuranosyl}-9h-purin-6-amine
CHEMBL4570249
AKOS040758327

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" These results suggest that individualized model-based dosing of fludarabine in infants and young children may reduce morbidity and mortality through improved rates of disease-free survival and limiting drug-related toxicity."( Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients.
Aweeka, F; Chan, D; Cowan, MJ; Dvorak, CC; Huang, L; Ivaturi, V; Jennissen, C; Liu, T; Long-Boyle, J; Orchard, PJ; Pai, SY; Stricherz, M; Tolar, J; Wahlstrom, J, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1541393Substrate activity at recombinant full-length chicken CGAS expressed in Escherichia coli BL21 (DE3) assessed as cyclic dinucleotide formation by measuring reaction conversion at 1 mM incubated for 16 hrs in presence of ATP by HPLC-UV analysis2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1541389Substrate activity at recombinant full-length mouse CGAS expressed in Escherichia coli BL21 (DE3) assessed as cyclic dinucleotide formation by measuring reaction conversion at 1 mM incubated for 16 hrs in presence of GTP by HPLC-UV analysis2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1541390Substrate activity at recombinant full-length chicken CGAS expressed in Escherichia coli BL21 (DE3) assessed as cyclic dinucleotide formation by measuring reaction conversion at 1 mM incubated for 16 hrs in presence of GTP by HPLC-UV analysis2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1541391Substrate activity at recombinant full-length human CGAS expressed in Escherichia coli BL21 (DE3) assessed as cyclic dinucleotide formation by measuring reaction conversion at 1 mM incubated for 16 hrs in presence of ATP by HPLC-UV analysis2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1541388Substrate activity at recombinant full-length human CGAS expressed in Escherichia coli BL21 (DE3) assessed as cyclic dinucleotide formation by measuring reaction conversion at 1 mM incubated for 16 hrs in presence of GTP by HPLC-UV analysis2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1541392Substrate activity at recombinant full-length mouse CGAS expressed in Escherichia coli BL21 (DE3) assessed as cyclic dinucleotide formation by measuring reaction conversion at 1 mM incubated for 16 hrs in presence of ATP by HPLC-UV analysis2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (22.73)18.7374
1990's9 (40.91)18.2507
2000's5 (22.73)29.6817
2010's3 (13.64)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (9.09%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]